Boston Scientific eyes FDA with new leads

Boston Scientific ($BSX) has launched a U.S. trial of two next-generation leads for defibrillators and pacemakers, working toward FDA approval after completing the first implant. The devices, Acuity X4 for pacers and Reliance 4-Front for ICDs, are quadripolar technologies, designed to maximize effectiveness by offering more flexible stimulation. Both are already CE marked and on the market overseas. More

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.